$26.56-$0.07 (-0.26%)
Principal Real Estate Active Opportunities ETF’s quoted price sits in the upper half of its reported 52-week range, 7.07% below the high.
Loading market information…
CBOE · HELX · USD
Stock price, dividends
Quote as of Oct 30, 2026, 07:59 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Franklin Genomic Advancements ETF’s quoted price sits in the upper half of its reported 52-week range, 2.1% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Franklin Genomic Advancements ETF’s forward annual dividend is $0.05 per share, paid monthly. The forward yield is 0.1% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
THE COMPANY BEHIND THE TICKER
This fund aims to generate substantial capital growth by strategically investing in a diverse array of equity securities. Its portfolio includes companies based within the United States as well as those operating in international markets, encompassing both established and emerging economies. The core investment thesis of the fund centers on companies engaged in genomic advancements. Specifically, it seeks out firms that the investment manager believes are fundamentally dedicated to, or are poised to significantly benefit from, efforts to prolong and enhance the overall quality of life for both humans and animals. This is accomplished by integrating cutting-edge technological and scientific innovations, improvements, and breakthroughs in the field of genomics directly into their business models and operations.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 31, 2026, 07:20 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
KEEP COMPARING
$26.56-$0.07 (-0.26%)
Principal Real Estate Active Opportunities ETF’s quoted price sits in the upper half of its reported 52-week range, 7.07% below the high.
$41.52-$0.32 (-0.77%)
Brendan Wood TopGun ETF’s quoted price sits in the upper half of its reported 52-week range, 4.11% below the high.
$21.40-$0.00 (-0.01%)
The Free Markets ETF’s quoted price sits in the lower half of its reported 52-week range, 8.63% below the high.
$38.25+$0.45 (+1.19%)
Horizon Kinetics Medical ETF’s quoted price sits in the upper half of its reported 52-week range, 0.55% below the high.
$21.53-$0.28 (-1.26%)
Adaptive Tactical Rotation ETF’s quoted price sits in the upper half of its reported 52-week range, 8.21% below the high.
$42.27-$0.61 (-1.43%)
Innovator U.S. Equity Accelerated Plus ETF - July’s quoted price sits in the upper half of its reported 52-week range, 2.04% below the high.
$25.21-$0.29 (-1.14%)
Rainwater Equity ETF’s quoted price sits in the upper half of its reported 52-week range, 6.63% below the high.
$14.81-$0.19 (-1.29%)
Global X - Nasdaq 100 Risk Managed Income ETF’s quoted price sits in the lower half of its reported 52-week range, 8.88% below the high.
